Intuitive Surgical, Inc. (ISRG)
Down 15% in 4 Weeks, Here's Why You Should You Buy the Dip in Intuitive Surgical (ISRG)
Intuitive Surgical (ISRG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It
Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Intuitive Surgical: The Correction Has Done The Work The Fundamentals Could Not
Intuitive Surgical, Inc. has declined ~38% since my previous Hold, driven by valuation concerns and recent structural headwinds. Despite ISRG's Q2 2026 earnings growth, margin expansion, and raised guidance, markets reacted to a slowdown in U.S. procedure growth. Pressures stem from expiring ACA subsidies impacting elective surgeries and weight loss drugs reducing bariatric procedure demand.
Why Intuitive Surgical Stock Dropped This Week
Intuitive Surgical posted strong sales and profit gains in the second quarter. But management issued a tepid forecast for the rest of 2026.
Why Intuitive Surgical's Strong Quarter Still Spooked Investors
Intuitive Surgical TodayISRGIntuitive Surgical$345.42 -56.91 (-14.15%) As of 07/17/2026 04:00 PM Eastern52-Week Range$344.55▼$603.88P/E Ratio39.57Price Target$523.46Add to WatchlistIntuitive Surgical NASDAQ: ISRG was part of the artificial intelligence (AI)/robotics trade before it became mainstream.
Intuitive Surgical Is Getting Punished For No Good Reason
Intuitive Surgical remains a buy despite a nearly 30% stock decline and post-earnings volatility. Adoption metrics are resilient, with strong system placements and installed base growth offsetting softer U.S. procedure growth. Profitability improved: Q2 non-GAAP gross margin expanded to 70%, operating margin to 42.1%, and EPS beat by $0.30.
Intuitive Surgical Q2: The Market Is Missing The Bigger Picture
Intuitive Surgical, Inc. remains a compelling long-term compounder, with operational improvements and robust growth prospects despite recent market headwinds. ISRG delivered solid Q2 results: revenue and EPS beat estimates, da Vinci procedures grew 20%, and gross margin reached 70%, reinforcing ISRG's strong positioning. Current valuation near a 5-year low—~35x forward earnings—offers a more attractive entry point, with multiple compression creating a margin of safety.
Why Intuitive Surgical Stock Plunged Today
Intuitive Surgical (ISRG) shares plummeted Friday after the maker of robotic surgical tools failed to raise the outlook for its flagship product despite better-than-expected second-quarter results.
ISRG Q2 Earnings Beat Estimates, Stock Falls on Slow Procedure Growth
ISRG beats second-quarter earnings and revenue estimates, but shares fall after hours as procedure growth slows sequentially despite strong placements.
Intuitive Surgical shares fall as procedure growth slows despite Q2 earnings beat
Intuitive Surgical (NASDAQ: ISRG) shares fell about 11% on Friday after the robotic surgery company reported second-quarter results that topped Wall Street expectations but disappointed investors with slower US procedure growth and a cautious full-year outlook. The company reported second quarter revenue of $2.89 billion, up 19% from a year earlier and above analysts' consensus estimate of $2.82 billion.
Intuitive Surgical falls as Obamacare concerns rekindle medtech demand debate
Intuitive Surgical shares fell more than 12% before the bell on Friday after it maintained its global growth forecast for procedures performed with its da Vinci surgical robots and warned that changes to some insurance plans could hurt demand.
Intuitive Surgical stock sinks despite earnings beat on 2026 procedure growth outlook
Shares of Intuitive Surgical tumbled about 12% in premarket trading on Friday after the robotic surgery company issued a full-year procedure growth outlook that fell short of investor expectations, overshadowing stronger-than-expected second-quarter earnings and revenue. The maker of the da Vinci robotic surgery platform reported adjusted earnings of $2.80 per share for the quarter, comfortably ahead of analysts' estimates of $2.51.
